CAR 在非 B 细胞恶性肿瘤中停滞了吗?我们身处何处,又将去向何方?
Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?
这些进展凸显了细胞疗法在高危白血病中的潜力,并强调了持续创新以改善这些历史上难治人群预后的重要性。
43.3分
★★☆☆☆
ALL SOURCES
Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?
这些进展凸显了细胞疗法在高危白血病中的潜力,并强调了持续创新以改善这些历史上难治人群预后的重要性。
Generation of ex vivo autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy.
淋巴祖细胞分化后,CD5 + 和 CD7 + 细胞显著增加 (65-84 %),而 CD34 + 细胞随之下降。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。